Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
1.740
+0.040 (2.35%)
At close: Sep 26, 2025, 4:00 PM EDT
1.770
+0.030 (1.72%)
After-hours: Sep 26, 2025, 7:44 PM EDT
Neumora Therapeutics Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Neumora Therapeutics stock ranges from a low of $1.00 to a high of $18. The average analyst price target of $5.83 forecasts a 235.06% increase in the stock price over the next year.
Price Target: $5.83 (+235.06%)
Analyst Consensus: Hold
* Price targets were last updated on Jul 16, 2025.
Analyst Ratings
The average analyst rating for Neumora Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 4 | 4 | 4 | 4 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Sep 16, 2025 |
| Mizuho | Mizuho | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +187.36% | Jul 16, 2025 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +187.36% | May 13, 2025 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +187.36% | Apr 10, 2025 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $7 → $1 | Strong Buy → Sell | Downgrades | $7 → $1 | -42.53% | Apr 2, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
4.25M
EPS This Year
-1.44
from -1.53
EPS Next Year
-1.03
from -1.44
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 26.3M | |||
| Avg | n/a | 4.3M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.39 | -0.61 | |||
| Avg | -1.44 | -1.03 | |||
| Low | -1.51 | -1.59 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.